Allergy drops under the microscope: do they really make life better for itchy eyes?
NCT ID NCT07149298
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This observational study looks at 100 patients with allergic conjunctivitis who received sublingual (under-the-tongue) allergen immunotherapy. Researchers will track changes in symptoms and quality of life using a standard questionnaire over 6 months. The goal is to see if this treatment helps people feel better day-to-day.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- sublingual allergen immunotherapy
- What this could lead to
- If successful, this study could show that sublingual allergen immunotherapy improves daily life for people with allergic conjunctivitis.
- What could go wrong
- This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
100 people
The number who actually took part.
- Started
-
Mar 2014
- Expected to finish
-
Mar 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
100 patients who attended the Conde de Valenciana Institute's Immunology Department from 2018 to 2023, diagnosed with conjunctivitis, treated with allergen-specific sublingual immunotherapy, completed 3 years of treatment, and completed at least eight quality-of-life questionnaires.
- Ages
-
6 to 86 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient records containing complete information * Both sexes * Age range: 6 to 86 years * Between 2018 and 2023 * Diagnosed with allergic conjunctivitis * Who have received treatment with allergen-specific sublingual immunotherapy * With 8 assessments from the immunology and cornea department * With 7 quality of life questionnaires completed by the patient Exclusion Criteria: * Patient records for other inflammatory ocular conditions * Those with chronic diseases * Those who have received naturopathic or immunomodulatory treatment during the follow-up period for allergen-specific sublingual immunotherapy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Allergic conjunctivitis of both eyes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Instituto de Oftalmología FAP Conde de Valenciana
Mexico City, 06800, Mexico
More trials for these conditions
Other studies related to the condition(s) this trial covers.